Journal
Multiple Sclerosis Journal
Publication Date
2-1-2024
Volume
30
Issue
2
First Page
177
Last Page
183
Document Type
Open Access Publication
DOI
10.1177/13524585231216854
Rights and Permissions
Naismith RT, Cohen JA, Bar-Or A, Comi G, Selmaj KW, Hartung HP, Sheffield JK, Krakovich A, Tatosian D, Cheng CY, Reardon J, Khaychuk V, Riolo JV, Silva D, Cree BA. Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial. Mult Scler. 2024 Feb;30(2):177-183. doi: 10.1177/13524585231216854. © The Author(s), 2023. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Request permissions for this article.
Recommended Citation
Naismith, Robert T; Cohen, Jeffrey A; Bar-Or, Amit; Comi, Giancarlo; Selmaj, Krzysztof W; Hartung, Hans-Peter; Sheffield, James K; Krakovich, Anthony; Tatosian, Daniel; Cheng, Chun-Yen; Reardon, Jennifer; Khaychuk, Vadim; Riolo, Jon V; Silva, Diego; and Cree, Bruce Ac, "Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial." Multiple Sclerosis Journal. 30, 2. 177 - 183. (2024).
https://digitalcommons.wustl.edu/oa_4/3238
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
